Clinical Trials
65 trialsPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Everolimus for Children With Recurrent or Progressive Ependymoma
University of Texas Southwestern Medical Center
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Children's Oncology Group
Ex Vivo Drug Sensitivity Testing and Mutation Profiling
Florida International University
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Pediatric Brain Tumor Consortium
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
Wake Forest University Health Sciences
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
Children's Oncology Group
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
National Cancer Institute (NCI)
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
University of Iowa
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
Children's Oncology Group
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
Duke University
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
National Cancer Institute (NCI)
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
Indiana University
Metabolic Syndrome in Childhood Cancer Survivors
University of Minnesota
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
Children's Oncology Group
Vinorelbine in Treating Children With Recurrent or Refractory Cancers
Children's Oncology Group
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
Duke University
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
National Cancer Institute (NCI)
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
Children's Oncology Group
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
University of South Florida
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
National Cancer Institute (NCI)
Cilengitide in Treating Children With Refractory Primary Brain Tumors
National Cancer Institute (NCI)
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
National Cancer Institute (NCI)
Lobradimil and Carboplatin in Treating Children With Brain Tumors
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
National Cancer Institute (NCI)
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
National Cancer Institute (NCI)
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
Duke University
Irinotecan in Treating Children With Refractory Solid Tumors
Children's Oncology Group
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
National Cancer Institute (NCI)
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
National Cancer Institute (NCI)
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
Duke University
Docetaxel in Treating Children With Recurrent Solid Tumors
National Cancer Institute (NCI)
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
National Cancer Institute (NCI)
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)